Publications by authors named "Lida Tehrani"

Claim this Profile
C
Correction to "Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation".
Stephen Norris, Xiaochu Ba, Jayce Rhodes, Dehua Huang, Gody Khambatta, Lida Tehrani

J Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.
Stephen Norris, Xiaochu Ba, Jayce Rhodes, Dehua Huang, Gody Khambatta, Lida Tehrani

J Med Chem· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity.
Jan Elsner, Dan Cashion, Dale Robinson, Sogole Bahmanyar, Lida Tehrani

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Jennifer R Riggs, Jan Elsner, Dan Cashion, Dale Robinson, Lida Tehrani

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Jennifer R Riggs, Mark Nagy, Jan Elsner, Paul Erdman, Dan Cashion, Lida Tehrani

J Med Chem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Gregory D Ferguson, Mercedes Delgado, Veronique Plantevin-Krenitsky, Kristen Jensen-Pergakes, R J Bates, Lida Tehrani

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.
Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, Jingjing Zhao, Garrick Packard, Lida Tehrani

J Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, Jan Elsner, Jingjing Zhao, Lida Tehrani

J Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Garrick K Packard, Patrick Papa, Jennifer R Riggs, Paul Erdman, Lida Tehrani

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
Tony Siu, Yiwei Li, Johnny Nagasawa, Jun Liang, Lida Tehrani

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
Lida R Tehrani, Nicholas D Smith, Dehua Huang, Steve F Poon, Jeffrey R Roppe

Bioorg Med Chem Lett· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
Peter C Chua, Johnny Y Nagasawa, Leo S Bleicher, Benito Munoz, Edwin J Schweiger, Lida Tehrani

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice.
Margaret J Bradbury, Una Campbell, Darlene Giracello, Deborah Chapman, Chris King, Lida Tehrani

J Pharmacol Exp Ther· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
Chris S Busse, Jesse Brodkin, David Tattersall, Jeffery J Anderson, Noelle Warren, Lida Tehrani

Neuropsychopharmacology· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
Dehua Huang, Steve F Poon, Deborah F Chapman, Janice Chung, Merryl Cramer, Lida Tehrani

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
Nicholas D Smith, Steve F Poon, Dehua Huang, Mitchell Green, Christopher King, Lida Tehrani

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor.
Essa Hu, Peter C Chua, Lida Tehrani, Johnny Y Nagasawa, Anthony B Pinkerton

Bioorg Med Chem Lett· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.
Jeffrey Roppe, Nicholas D Smith, Dehua Huang, Lida Tehrani, Bowei Wang

J Med Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.
Jeffrey R Roppe, Bowei Wang, Dehua Huang, Lida Tehrani, Theodore Kamenecka

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor.
Nicholas D P Cosford, Jeffrey Roppe, Lida Tehrani, Edwin J Schweiger, T Jon Seiders

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
Nicholas D P Cosford, Lida Tehrani, Jeffrey Roppe, Edwin Schweiger, Nicholas D Smith

J Med Chem· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization.
Jeffery J Anderson, Sara P Rao, Blake Rowe, Darlene R Giracello, Greg Holtz, Lida Tehrani

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis